Download PDF
Diabetologie und Stoffwechsel 2019; 14(05): 370-378
DOI: 10.1055/a-0876-6081
CME-Fortbildung
© Georg Thieme Verlag KG Stuttgart · New York

Diabetische Pneumopathie

Diabetic pneumopathy
Stefan Kopf
Further Information

Publication History

Publication Date:
05 November 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Breathlessness or dyspnea is a frequent symptom in patients with diabetes and the first disease which has to be excluded is the coronary heart disease. However, previous epidemiological studies have shown that patients with diabetes mellitus have an increased risk for fibrotic pulmonary diseases, such as the idiopathic pulmonary fibrosis (IPF). Recent studies were able to show that patients with newly diagnosed type 2 diabetes have impaired pulmonary oxygen consumption and over 26 % of patients with long-term type 2 diabetes showed restrictive lung function with fibrotic interstitial lung diseases. Especially patients with type 2 diabetes and nephropathy had an 8-fold higher risk for lung diseases. This is not surprising since the pathomechanisms of pulmonary fibrosis and diabetic complications have much in common: reactive oxygen species induce DNA-damage with consecutive activation of inflammatory cytokines which induce fibrotic remodeling of the tissue. This leads us to the suggestion that patients with diabetes, albuminuria and breathlessness should be examined for interstitial lung disease on regular basis. However, data regarding the natural course of diabetic pneumopathy and therapeutic approaches are still missing. Small intervention studies with IPF-patients could show that sports and physical activity were able to stabilize the disease progression.

Diabetes mellitus ist eine Systemerkrankung, und betroffene Patienten werden regelmäßig auf makro- und mikrovaskuläre Folgeerkrankungen untersucht. Die Lunge als mögliches betroffenes Organ wird dabei nicht beachtet – obwohl mehrere Studien darauf hinweisen, dass sie ein Zielorgan für diabetische Folgeschäden ist. Dieser Beitrag fasst den aktuellen Wissensstand zu Pathogenese, Diagnostik und Therapie der diabetischen Pneumopathie zusammen.

Schlüsselwörter

Diabetes mellitus - interstitielle Lungenerkrankung - Lungenfibrose - diabetische Pneumopathie - Lungenfunktionsprüfung

Key words

diabetes mellitus - interstitial lung disease - pulmonary fibrosis - diabetic pneumopathy - pulmonary function testing
 

  • Literatur

  • 1 Berliner D, Schneider N, Welte T. et al. The differential diagnosis of dyspnea. Dtsch Arztebl Int 2016; 113: 834-845
    PubMedGoogle Scholar
  • 2 Frese T, Sobeck C, Herrmann K. et al. Dyspnea as the reason for encounter in general practice. J Clin Med Res 2011; 3: 239-246
    PubMedGoogle Scholar
  • 3 Quanjer PH, Stanojevic S, Cole TJ. et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324-1343
    CrossrefPubMedGoogle Scholar
  • 4 Robinson PD, Latzin P, Verbanck S. et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J 2013; 41: 507-522
    CrossrefPubMedGoogle Scholar
  • 5 Adeloye D, Chua S, Lee C. et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health 2015; 5: 020415
    CrossrefPubMedGoogle Scholar
  • 6 Salvi S. Tobacco smoking and environmental risk factors for chronic obstructive pulmonary disease. Clin Chest Med 2014; 35: 17-27
    CrossrefPubMedGoogle Scholar
  • 7 Bokov P, Delclaux C. Interpretation and use of routine pulmonary function tests: Spirometry, static lung volumes, lung diffusion, arterial blood gas, methacholine challenge test and 6-minute walk test. Rev Med Interne 2016; 37: 100-110
    CrossrefPubMedGoogle Scholar
  • 8 Scarlata S, Costanzo L, Giua R. et al. Diagnosis and prognostic value of restrictive ventilatory disorders in the elderly: a systematic review of the literature. Exp Gerontol 2012; 47: 281-289
    CrossrefPubMedGoogle Scholar
  • 9 Hyldgaard C, Hilberg O, Muller A. et al. A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014; 108: 793-799
    CrossrefPubMedGoogle Scholar
  • 10 Olson AL, Swigris JJ. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med 2012; 33: 41-50
    CrossrefPubMedGoogle Scholar
  • 11 King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961
    CrossrefPubMedGoogle Scholar
  • 12 Raghu G, Collard HR, Egan JJ. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824
    CrossrefPubMedGoogle Scholar
  • 13 Kim YJ, Park JW, Kyung SY. et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus: the national survey in Korea from 2003 to 2007. J Korean Med Sci 2012; 27: 756-760
    CrossrefPubMedGoogle Scholar
  • 14 Enomoto T, Usuki J, Azuma A. et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 2003; 123: 2007-2011
    CrossrefPubMedGoogle Scholar
  • 15 Vracko R, Thorning D, Huang TW. Basal lamina of alveolar epithelium and capillaries: quantitative changes with aging and in diabetes mellitus. Am Rev Respir Dis 1979; 120: 973-983
    PubMedGoogle Scholar
  • 16 Sandler M. Is the lung a “target organ” in diabetes mellitus?. Arch Intern Med 1990; 150: 1385-1388
    CrossrefPubMedGoogle Scholar
  • 17 Klein OL, Krishnan JA, Glick S. et al. Systematic review of the association between lung function and Type 2 diabetes mellitus. Diabet Med 2010; 27: 977-987
    CrossrefPubMedGoogle Scholar
  • 18 van den Borst B, Gosker HR, Zeegers MP. et al. Pulmonary function in diabetes: a metaanalysis. Chest 2010; 138: 393-406
    CrossrefPubMedGoogle Scholar
  • 19 Caughey GE, Preiss AK, Vitry AI. et al. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care 2013; 36: 3009-3014
    CrossrefPubMedGoogle Scholar
  • 20 Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J 2007; 30: 835-839
    CrossrefPubMedGoogle Scholar
  • 21 Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet 2017; 389: 1941-1952
    CrossrefPubMedGoogle Scholar
  • 22 Kreuter M, Ehlers-Tenenbaum S, Palmowski K. et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11: e0151425
    CrossrefPubMedGoogle Scholar
  • 23 Röhling M, Pesta D, Markgraf DF. et al. Metabolic determinants of impaired pulmonary function in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2018; 126: 584-589
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Kopf S, Groener JB, Kender Z. et al. Breathlessness and restrictive lung disease: an important diabetes-related feature in patients with type 2 diabetes. Respiration 2018; 96: 29-40
    CrossrefPubMedGoogle Scholar
  • 25 Selman M, King TE, Pardo A. et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134: 136-151
    Google Scholar
  • 26 Cheresh P, Kim SJ, Tulasiram S. et al. Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta 2013; 1832: 1028-1040
    PubMedGoogle Scholar
  • 27 Groener JB, Oikonomou D, Cheko R. et al. Methylglyoxal and advanced glycation end products in patients with diabetes – what we know so far and the missing links. Exp Clin Endocrinol Diabetes 2019; 127: 497-504
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Jagadapillai R, Rane MJ, Lin X. et al. Diabetic microvascular disease and pulmonary fibrosis: the contribution of platelets and systemic inflammation. Int J Mol Sci 2016; 17: pii: E1853
    CrossrefPubMedGoogle Scholar
  • 29 Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 2001; 15: 203-210
    CrossrefPubMedGoogle Scholar
  • 30 Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Med 2017; 130: S40-S50
    CrossrefPubMedGoogle Scholar
  • 31 Nersisson R, Noel MM. Heart sound and lung sound separation algorithms: a review. J Med Eng Technol 2017; 41: 13-21
    CrossrefPubMedGoogle Scholar
  • 32 Padilla-Ortiz AL, Ibarra D. Lung and heart sounds analysis: state-of-the-art and future trends. Crit Rev Biomed Eng 2018; 46: 33-52
    CrossrefPubMedGoogle Scholar
  • 33 Bestall JC, Paul EA, Garrod R. et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586
    CrossrefPubMedGoogle Scholar
  • 34 Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998; 158: 1384-1387
    CrossrefPubMedGoogle Scholar
  • 35 Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci 1989; 76: 277-282
    CrossrefPubMedGoogle Scholar
  • 36 Stanojevic S. Standardisation of lung function test interpretation: Global Lung Function Initiative. Lancet Respir Med 2018; 6: 10-12
    CrossrefPubMedGoogle Scholar
  • 37 Travis WD, Costabel U, Hansell DM. et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-748
    CrossrefPubMedGoogle Scholar
  • 38 Oh IH, Park JH, Lee CH. et al. The association of normal range glycated hemoglobin with restrictive lung pattern in the general population. PLoS One 2015; 10: e0117725
    CrossrefPubMedGoogle Scholar
  • 39 Spagnolo P, Kreuter M, Maher TM. et al. Metformin does not affect clinically relevant outcomes in patients with idiopathic pulmonary fibrosis. Respiration 2018; 96: 314-322
    CrossrefPubMedGoogle Scholar
  • 40 Gaunaurd IA, Gómez-Marín OW, Ramos CF. et al. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care 2014; 59: 1872-1879
    CrossrefPubMedGoogle Scholar
  • 41 Vainshelboim B. Exercise training in idiopathic pulmonary fibrosis: is it of benefit?. Breathe 2016; 12: 130-138
    CrossrefPubMedGoogle Scholar